Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03601897 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Deciphera Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 177
- Enrollment target
NCT03601897 is a Phase 1 study that was terminated before completion, run by Deciphera Pharmaceuticals. The registered enrollment target is 177 participants.
The verdict
NCT03601897, a Phase 1 study, was terminated before completion, sponsored by Deciphera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 177 participants
- Enrollment target
Study Summary
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors.
Interventions
- DRUG Paclitaxel
- DRUG Rebastinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2018-10-25 |
| Est. Completion | 2022-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03601897
The ClinicalTrials.gov registry entry for NCT03601897 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT03601897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03601897 about?
NCT03601897 is a clinical study titled "A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors". This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors.
What is the current status of trial NCT03601897?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2018-10-25. Estimated completion is 2022-05-23.
What interventions are being tested in trial NCT03601897?
The interventions under investigation include: Paclitaxel (DRUG), Rebastinib (DRUG).
Who is sponsoring clinical trial NCT03601897?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.